BA.3.2 Cicada Is Now in 23+ Countries. What the Global Data Shows — and What Experts Say About the Risk

BA.3.2 — the COVID subvariant circulating under the informal nickname "Cicada" — has now been confirmed in at least 23 countries across Africa, Asia, Europe, North America, and Oceania. In parts of Europe it has already become the dominant circulating variant. In the United States it is widespread but not yet dominant. The global picture at the end of March 2026 is of a variant that has established itself across most major regions — while health authorities in all of those regions continue to assess it as not more severe than variants currently circulating.

Europe: already dominant in several countries

Europe is currently the region with the highest documented BA.3.2 prevalence. In Germany and the Netherlands, BA.3.2 exceeded 40% of sequenced samples by early 2026, according to ECDC data. Denmark was among the first European countries to report elevated BA.3.2 proportions, reaching approximately 30% of sequences in late 2025. Detections have been confirmed across France, Belgium, Italy, Luxembourg, Norway, Ireland, Slovenia, Spain, Sweden, and Czechia.

The European Centre for Disease Prevention and Control (ECDC) has assessed BA.3.2 as unlikely to be associated with any increase in infection severity or reduction in vaccine effectiveness against severe disease. The ECDC notes that EU and EEA populations have significant hybrid immunity from prior infection plus vaccination, which provides continued protection against severe outcomes.

Asia-Pacific: confirmed spread, subvariant emerging

In Asia, BA.3.2 has been confirmed in Japan, Hong Kong, South Korea, and Singapore — countries with strong genomic sequencing capacity. These countries have consistently reported some of the highest BA.3.2 sequence shares in Asia. Australia has also confirmed BA.3.2 circulation, with a notable development: a subvariant called BA.3.2.2 has been detected and is showing growth, particularly in Western Australia. The emergence of BA.3.2.2 indicates the virus is continuing to evolve within this lineage.

United States: in 29 states but not yet dominant

In the US, BA.3.2 has been detected in 29 states and Puerto Rico. That is a significant geographic footprint — but geographic spread is not the same as dominance. As of mid-March, BA.3.2 accounted for approximately 3.7% of national wastewater samples. The most common circulating variant in the US remains XFG, which makes up roughly 53% of wastewater detections. The CDC confirmed BA.3.2 in wastewater from 25 states, three major airports (SFO, JFK, and Dulles), and in a small number of clinical cases — all of which recovered.

Origin and why it went unnoticed for years

BA.3.2 was first identified in South Africa in November 2024. It descends from the BA.3 lineage, which last circulated at detectable levels in early 2022 — nearly three years earlier. That long dormancy followed by reemergence is the origin of the "Cicada" nickname. The first US traveller case was detected in June 2025. By late 2025 it had reached Europe and Asia, and by early 2026 it was circulating on every inhabited continent.

What experts are saying

Multiple infectious disease researchers across institutions have assessed BA.3.2 over the past weeks. The consistent message is that there is no evidence the variant causes more severe disease than other recent Omicron-lineage variants. Dr. Adolfo García-Sastre at Mount Sinai described it as "not a more problematic strain than previous ones." Researchers at Stony Brook Medicine and Northeastern University have offered similar assessments. The ECDC's population-level analysis points to hybrid immunity as the key reason why high prevalence in Europe has not translated into elevated hospitalisations.

Vaccines and antivirals

Current 2025-26 vaccines show reduced antibody neutralisation against BA.3.2 in laboratory tests due to the variant's 70-75 spike protein mutations. However, health authorities in Europe and the US agree that T-cell immunity — which is less affected by spike protein changes — continues to provide meaningful protection against severe disease and death. Paxlovid (nirmatrelvir/ritonavir) and other approved antivirals remain fully effective, as the mutations that affect antibody recognition do not affect the viral protease that antivirals target.

Who should pay attention

The same groups that face higher risk from any COVID variant remain at higher risk from BA.3.2 globally: people who are immunocompromised, older adults, and those with conditions such as diabetes, heart disease, or lung disease. For these groups, staying current with COVID vaccination and being aware of antiviral eligibility is the relevant guidance regardless of country.